{"id":"NCT03208985","sponsor":"HRA Pharma","briefTitle":"A Study of Use of Ella®, an Emergency Contraceptive, Under Simulated OTC Conditions","officialTitle":"A Multi-Center, Open-Label Trial Investigating Behavior Related to Ella® Use in a Simulated OTC Environment (LIBRella)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-05-23","primaryCompletion":"2018-06-14","completion":"2018-06-14","firstPosted":"2017-07-06","resultsPosted":"2022-12-02","lastUpdate":"2022-12-02"},"enrollment":1270,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"OTHER"},"conditions":["Emergency Contraception"],"interventions":[{"type":"DRUG","name":"Use Phase (Ulipristal Acetate, 30 mg)","otherNames":[]}],"arms":[{"label":"Use Phase (Ulipristal Acetate, 30 mg)","type":"EXPERIMENTAL"}],"summary":"This study is designed to assess whether consumers select and use ella® (ulipristal acetate 30mg), an emergency contraceptive, in a manner consistent with the OTC package directions in an OTC-like setting.","primaryOutcome":{"measure":"Proportion of Dosing Instances Among User Population Taken Within 120 Hours (5 Days) of Most Recent Episode of Unprotected Sex.","timeFrame":"Up to 6 Weeks","effectByArm":[{"arm":"Use Phase (Ulipristal Acetate, 30 mg)","deltaMin":704,"sd":null}],"pValues":[]},"eligibility":{"minAge":null,"sex":"FEMALE","healthyVolunteers":true,"inclusionCount":1,"exclusionCount":2},"locations":{"siteCount":34,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":15,"n":783},"commonTop":["Abdominal pain lower","Nausea","Fatigue","Urinary tract infection","Viral upper respiratory tract infection"]}}